XPro1595 shows statistically significant effect on white matter MRI biomarker in Alzheimer's trial

INmune Bio reported Phase 2 MINDFuL trial results showing XPro1595 demonstrated significant treatment effects on advanced white matter MRI biomarkers (p=0.0028), with stronger efficacy in inflammation-enriched patients. The findings support the company's precision-medicine approach and align with its Phase 2b/3 registrational program design, bolstered by recent FDA Fast Track designation.